2m 2m 2m 2m 2m 2m 2m
X4 PHARMA (XFOR)
NASDAQ
$4.06+$0.09 (+2.34%)
Price as of Jun 03, 2026 7:55 PM EDT- $406.5MMarket Cap
- 2.02%1-Year Change
- BiotechnologyIndustry
X4 PHARMA (XFOR)
$4.06+$0.09 (+2.34%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 28.6M +1,018.11% | 2.6M -98.30% | 150.0M N/A | 0 N/A | |
Cost of Revenue | 5.8M +622.33% | 797,000 N/A | N/A N/A | N/A N/A | |
Gross Profit | 22.8M +1,197.33% | 1.8M -98.83% | 150.0M N/A | 0 N/A | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -72.7M -10.93% | -81.6M +13.37% | -72.0M +17.95% | -61.1M +20.56% | |
Depreciation and Amortization Expense | 1.3M +60.43% | 796,000 +89.98% | 419,000 -18.32% | 513,000 +2.81% | |
Total Operating Expenses | 43.5M +11.70% | 39.0M -63.77% | 107.5M +22.79% | 87.6M +2.89% | |
Operating Profit | -86.9M +138.68% | -36.4M -66.15% | -107.5M +22.79% | -87.6M +2.89% | |
Interest Income | 4.6M -20.68% | 5.8M +25.91% | 4.6M +1,992.24% | 219,000 +2,090.00% | |
Interest Expense | -8.9M +1.23% | -8.8M +51.77% | -5.8M +44.68% | -4.0M +9.64% | |
Interest Income and Expense and Net | -4.3M +43.38% | -3.0M +150.96% | -1.2M -68.34% | -3.8M +3.91% | |
Total Nonoperating Income and Expense | 7.7M +1,145.33% | -739,000 -111.49% | 6.4M +202.60% | -6.3M +75.53% | |
Income before Taxes | -79.2M +113.13% | -37.1M -63.26% | -101.1M +7.73% | -93.8M +5.82% | |
Income Taxes | 41,000 -86.77% | 310,000 +297.44% | 78,000 +178.57% | 28,000 +64.71% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -79.2M +111.48% | -37.5M -62.98% | -101.2M +7.78% | -93.9M +5.83% | |
Net Income from Continuing Operations Applicable to Common | -79.2M +111.37% | -37.5M -62.98% | -101.2M +4.93% | -96.4M -6.07% | |
Basic EPS and Net Income | -1.87 +884.21% | -0.19 -66.67% | -0.57 -62.50% | -1.52 -61.90% | |
Diluted EPS and Net Income | -1.87 +884.21% | -0.19 -66.67% | -0.57 -62.50% | -1.52 -61.90% | |
Basic Weighted Average Shares | 42.3M -78.97% | 201.1M +13.08% | 177.8M +179.91% | 63.5M +146.71% | |
Diluted Weighted Average Shares | 42.3M -78.97% | 201.1M +13.08% | 177.8M +179.91% | 63.5M +146.71% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 217.0M +289.68% | 55.7M -43.86% | 99.2M -18.49% | 121.7M +48.82% | |
Short-Term Investments | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash and Cash Equivalents and Short-Term Investments | 217.0M +289.68% | 55.7M -43.86% | 99.2M -18.49% | 121.7M +48.82% | |
Total Current Assets | 261.6M +133.19% | 112.2M -8.11% | 122.1M -5.13% | 128.7M +46.43% | |
Accumulated Depreciation | 1.2M -35.26% | 1.9M +17.54% | 1.6M +31.84% | 1.2M +69.61% | |
Property and Plant and Equipment and Net | 182,000 -76.55% | 776,000 +4.16% | 745,000 -32.52% | 1.1M -27.08% | |
Total Long-Term Assets | 692,000 -66.73% | 2.1M +44.85% | 1.4M +17.22% | 1.2M -28.90% | |
Total Assets | 290.5M +98.34% | 146.4M -0.55% | 147.3M -5.35% | 155.6M +32.78% | |
Income Taxes Payable | 0 N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | 0 -100.00% | 1.3M +65.41% | |
Total Current Liabilities | 25.8M -21.66% | 32.9M +43.81% | 22.9M +2.41% | 22.3M +59.20% | |
Total Long-Term Debt | 75.0M 0.00% | 75.0M -31.55% | 109.6M +69.08% | 64.8M -1.27% | |
Total Long-Term Liabilities | 525,000 -36.82% | 831,000 +92.36% | 432,000 +149.71% | 173,000 -79.06% | |
Total Liabilities | 104.2M -16.19% | 124.3M +29.26% | 96.2M +17.94% | 81.5M +54.53% | |
Retained Earnings | -594.6M +15.37% | -515.4M +7.84% | -477.9M +26.85% | -376.7M +33.18% | |
Total Stockholders Equity | 186.3M +741.08% | 22.1M -56.65% | 51.1M -30.99% | 74.1M +14.96% | |
Total Shares Outstanding | 90.9M -46.82% | 170.9M +2.10% | 167.4M +37.62% | 121.7M +332.55% | |
Cash Flow | |||||
Cash from Operating Activities | -85.6M -34.59% | -130.9M +35.63% | -96.5M +25.17% | -77.1M +8.74% | |
Capital Expenditures | 0 -100.00% | 326,000 +443.33% | 60,000 -41.75% | 103,000 -83.25% | |
Cash from Investing Activities | 8.2M -87.83% | 67.0M +550.11% | -14.9M +14,349.51% | -103,000 -83.25% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 238.6M +1,075.85% | 20.3M -77.07% | 88.5M -24.49% | 117.2M +57.90% | |
Financials Ratio | |||||
Gross Margin | 79.86% +16.03% | 68.83% N/A | N/A N/A | N/A N/A | |
Operating Margin | -303.89% -78.65% | -1,423.58% +1,885.99% | -71.68% N/A | N/A N/A | |
Return on Assets | -36.25% +42.16% | -25.50% -61.83% | -66.81% -2.93% | -68.83% -6.86% | |
Return on Equity | -75.99% -25.68% | -102.26% -36.75% | -161.67% +19.24% | -135.58% +4.87% | |
Revenue Growth | 1,018.11% +1,135.76% | -98.30% N/A | N/A N/A | N/A N/A | |
Current Ratio | 10.16 +197.64% | 3.41 -36.10% | 5.34 -7.36% | 5.76 -8.02% | |
Cash Ratio | 8.43 +397.39% | 1.69 -60.96% | 4.34 -20.40% | 5.45 -6.52% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | 2.14 +140.15% | 0.89 -13.43% | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | 0.74 +75.08% | 0.43 -25.04% | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow